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Cutaneous wound healing through paradoxical
MAPK activation by BRAF inhibitors
Helena Escuin-Ordinas1, Shuoran Li2, Michael W. Xie3, Lu Sun4, Willy Hugo4, Rong Rong Huang5, Jing Jiao6,7,
Felipe Meira de-Faria6,8, Susan Realegeno9, Paige Krystofinski1, Ariel Azhdam1, Sara Marie D. Komenan10,
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Harvey R. Herschman6,7,11, Roger S. Lo4,6,11, William H. McBride3,10, Tatiana Segura2 & Antoni Ribas1,6,10,11
BRAF inhibitors are highly effective therapies for the treatment of BRAFV600-mutated
melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due
to paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in BRAF
wild-type cells. Most of these hyperproliferative skin changes improve when a MEK inhibitor
is co-administered, as it blocks paradoxical MAPK activation. Here we show how the BRAF
inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and
migration of human keratinocytes through extracellular signal-regulated kinase (ERK) phos-
phorylation and cell cycle progression. Topical treatment with vemurafenib in two wound-
healing mice models accelerates cutaneous wound healing through paradoxical MAPK acti-
vation; addition of a mitogen-activated protein kinase kinase (MEK) inhibitor reverses the
benefit of vemurafenib-accelerated wound healing. The same dosing regimen of topical BRAF
inhibitor does not increase the incidence of cutaneous squamous cell carcinomas in mice.
Therefore, topical BRAF inhibitors may have clinical applications in accelerating the healing of
skin wounds.
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P
aradoxical MAPK activation has long been recognized as a
property of BRAF inhibitors1, where the preferential
binding of the BRAF inhibitor to a BRAF protomer
results in transactivation of its CRAF heterodimer partner.
In the setting of strong upstream RAS-GTP signalling,
membrane-localized RAF complexes then drive MEK/ERK
activation, increased MAPK transcriptional output and
enhanced cell proliferation (representative schematic of
paradoxical MAPK activation in Supplementary Fig. 1)2–5.
In this study we show how we can take advantage of the
mechanistic understanding of the skin hyperproliferative side
effects of BRAF inhibitors to accelerate skin wound healing by
inducing paradoxical MAPK activation in keratinocytes, which
are the predominant cells in the epidermis. Keratinocytes play a
major role in the initial proliferation stage of wound healing,
restoring the barrier function of the epithelium6,7. We
hypothesized that paradoxical MAPK activation induced by a
BRAF inhibitor in these BRAF wild-type cells would accelerate
cutaneous wound healing.
In our studies we demonstrate that vemurafenib promotes
both proliferative and migratory effects on adult human
epithelial keratinocytes (HEKa) in vitro by inducing
phosphorylation of pErk and activation of the proliferative
marker Ki67. Adding trametinib, a MEK inhibitor, to the
vemurafenib-treated cultures, offsets proliferation and migration.
Topical application of vemurafenib accelerates the healing of skin
wounds in two cutaneous wound-healing murine models without
promoting skin carcinogenesis. Consequently, topical BRAF
inhibitors may be used to improve the healing of acute skin
wounds.
Results
Vemurafenib effects on keratinocytes. We tested the effects of
vemurafenib on HEKa cultured as a monolayer and subjected to a
scratch, after which proliferating keratinocytes will grow to cover
and heal the scratch. Replicate cultures with or without vemur-
afenib were placed in an incubator with an automated microscope
analyzer to record the number of nucleated cells populating the
original scratch region over time. Vemurafenib enhanced the
covering of the scratch at 6, 8 and 12 h (Supplementary Fig. 2 and
Supplementary Movies 1 and 2). Vemurafenib induced both
proliferative and migratory effects on HEKa cells in vitro as
combination cultures containing mitomycin C, a mitosis inhi-
bitor, or NSC 295642, an inhibitor of cell motility, abolished both
effects of vemurafenib using an assay in which migration and
growth were initiated by removal of a central space sealant
(Supplementary Fig. 3a). The enhanced proliferation and
migration was inhibited by adding trametinib, a MEK inhibitor,
to the vemurafenib-treated cultures (Supplementary Fig. 3b).
Three-dimensional soft agar assays showed proliferation of
HEKa colonies upon exposure to vemurafenib, while the
BRAFV600E mutant melanoma line M249 had the expected
opposite effect of decrease in colonies (Supplementary Fig. 4a,b).
HEKa colonies not only increased in number but their mean
spot size also increased significantly (P¼ 0.007 by t-test,
Supplementary Fig. 4c). Addition of trametinib decreased the
number and size of HEKa colonies induced by vemurafenib
(Supplementary Fig. 5).
In HEKa and human BRAFV600E melanoma cultures, we
analysed MAPK signalling by western blot (Fig. 1a,b), as well as
pERK and cell proliferation by quantitative intracellular flow
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Figure 1 | BRAF inhibition induces paradoxical MAPK activation in keratinocytes (HEKa). (a) Western blot analyses of pERK in HEKa compared with the
BRAFV600E mutant melanoma cell line M249 when treated with vemurafenib. (b) Levels of pERK and pMEK in HEKa compared with the BRAFV600E mutant
melanoma line M249 when treated with vemurafenib (VEM), trametinib (TRAME) or the combination for 24 h. (c) Histograms of intracellular flow
cytometry analyses of HEKa and M249 cells treated with vehicle or vemurafenib (1.5 mM) and stained with pERK and Ki67 (staining controls represented in
Supplementary Fig. 6). (d) Quantification of fold-change of pERK and Ki67 levels in three replicate cultures of HEKa and M249 cells treated with
vemurafenib compared to vehicle. Error bars, mean±s.d.; n¼ 3. Results are representative of two experiments.
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cytometry (Fig. 1c,d and Supplementary Fig. 6). Vemurafenib
decreased pERK in the BRAFV600E mutant human melanoma cell
line M249, as expected, whereas it induced a paradoxical increase
in pERK in HEKa cells. Furthermore, in the presence of
vemurafenib, the proliferative marker Ki67 decreased in M249
melanoma cells while it increased in HEKa cells (Fig. 1c,d).
Vemurafenib enhances and trametinib inhibits wound healing.
We used two cutaneous wound-healing murine models to test the
effects of vemurafenib to improve the healing of skin wounds. In
an incisional wound-healing mice model (Fig. 2a), vemurafenib
or vehicle control was applied topically every other day for seven
doses in eight mice per group. On day 14, the gain in wound
tensile strength (WTS, in gram force per 2mm (gf per 2mm))
was analysed using a tensiometer. In three independent replicate
experiments (eight mice per group in each experiment;
seven strips per wound), vemurafenib-treated mice significantly
improved WTS compared with vehicle-treated controls (52%,
33% and 42%, respectively; Po0.0001 by t-test for all three
experiments; Fig. 2b). The administration of trametinib in
addition to vemurafenib reduced the WTS by 51% compared with
when using vemurafenib alone (Po0.0001 by t-test). Trametinib
on its own inhibited wound healing to a point where the skin
wound closure was too compromised and the WTS could not be
assessed (Fig. 2c,d). The area of the wounds and their
surroundings were analysed histologically by two pathologists
blinded to the study groups (RRH and AJC). Vemurafenib-
treated wounds displayed an accelerated proliferative stage of
wound healing as evidenced by quantitating the extent of epi-
dermal hyperplasia on both sides of the healing wounds. No
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Figure 2 | BRAF inhibition accelerates and MEK inhibition suppresses wound healing. (a) Schematic representation of the wound-healing studies
performed in C3H mice. (b) Wound tensile strength (WTS) using 2mm strips of wound-containing skin in three replicate experiments, each with eight
mice per group. WTS is represented as gram force (gf) per 2mm strip (Po0.0001). (c) Representative images of mice treated topically with vehicle,
vemurafenib (VEM, 2mg), trametinib (TRAME, 0.2mg) and the combination of vemurafenib and trametinib (VEMþTRAME) on days 2, 6 and 14.
(d) WTS in 8 mice per group, as gram force (gf) comparing vehicle, vemurafenib and the combination of vemurafenib and trametinib (Po0.0001).
Error bars in b and d, mean±s.d.; n¼8. Every graph represents one experiment with 8 replicates.
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re-epithelialization was observed in the trametinib alone and
vemurafenib plus trametinib groups at this time point
(Supplementary Fig. 7).
Vemurafenib enhances re-epithelialization. In an excisional
wound-splinting model in Balb/c mice8, we induced 6-mm round
wounds on the back of mice; splinting rings were tightly adhered
and sutured to the skin around the wounds, preventing wound
closure caused by skin contraction (representative images in
Supplementary Fig. 8). Vemurafenib (2mg) or DMSO was
applied on the wounds on days 0, 2 and 4, and per cent wound
closure was sequentially measured. The wounds treated with
vemurafenib showed a significantly higher percentage of wound
closure compared with the ones treated with vehicle on days 2,
6 and 14 (P¼ 0.004, n¼ 6; P¼ 0.02, n¼ 4; P¼ 0.0002, n¼ 6,
respectively, by t-test; Fig. 3a,b). The area of the wounds and their
surroundings were analysed histologically and pERKþ and
Ki67þ cells were quantified using digital pathology (Fig. 3c,d).
Compared with controls, the healing process in the presence of
vemurafenib was accelerated showing re-epithelialization by day 6
(Supplementary Fig. 9). The skin surface integrity was re-
established by day 14 in the vemurafenib-treated wounds,
whereas remodelling and dermal reparative fibrosis was delayed
in the control group (Fig. 3c). The number of pERKþ and
Ki67þ cells in the wounds treated with vemurafenib was
statistically significantly higher by day 14 compared with the
control group (P¼ 0.02 by t-test; n¼ 4; Fig. 3c,d), demonstrating
paradoxical MAPK leading to enhanced epithelial cell
proliferation.
Vemurafenib upregulates MAPK and wound-healing-related
signatures. To further characterize epithelial skin repair, the skin
samples obtained from the incisional wound-healing model were
analysed by RNASeq. The list of differentially expressed genes on
day 2, 6 and 14 (Supplementary Data 1) was compared with
published data for the transcripts that were differentially modu-
lated by blocking oncogenic MAPK signalling downstream
of mutated BRAFV600E using BRAF inhibitors9, and to genes
within the gene ontology term ‘wound healing’ (GO:0042060)10.
By day 6, both signatures were enriched significantly in the
vemurafenib-treated samples compared to their respective
controls (overall enrichment scores were computed based on
Single-sample Gene Set Variation Analysis (GSVA)11 (Fig. 4). A
more pronounced decrease of both the BRAFV600E and wound-
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Figure 3 | BRAF inhibition accelerates wound healing in an excisional wound model. (a) Representative images of vehicle-treated and vemurafenib
(VEM)-treated mice on day 0 and day 14. Original wound area is marked with dotted circles and amplified on the right side. (b) Percentage of wound
closure on day 2, 6 and 14. (**P¼0.004 (n¼6), *P¼0.02 (n¼4; two mice died due to haemorrhagic wounds), ***P¼0.0002 (n¼ 6)). (c) Representative
photomicrograph hematoxylin and eosin (H&E), pERK and Ki67 staining images in the presence and absence of vemurafenib by day 14. (d) Bar graph
representing the quantification of pERKþ and Ki67þ cells in the vehicle- and vemurafenib-treated wounds on day 14 (*P¼0.02; n¼4). Error bars in b
and d, mean±s.d. Bar graphs represent one experiment with 4 to 6 replicates per group.
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healing signatures was observed in the vemurafenib-treated
wounds by day 14, consistent with a more rapid healing.
Additionally, our gene output was compared with an early stage
wound-healing signature, with mostly pro-inflammatory genes
involved in the first stages of wound healing12 and a post-
operatory wound-healing signature13. These two wound-healing
signatures were also enriched by day 6 in the vemurafenib-treated
groups as opposed to the control group (Supplementary Fig. 10
and Supplementary Data 2). Genes recognized to be associated
with wound healing14 were upregulated in vemurafenib-
accelerated wound-healing wounds compared with control
wounds (Fig. 4 and Supplementary Fig. 10).
Transcriptional signature in vemurafenib-treated wounds.
Enrichment of signatures for dendritic cells, macrophages,
monocytes, fibroblasts and vascular and lymphatic endothelial
cells was observed in the wounds treated with vemurafenib as
compared with the control wounds (Supplementary Fig. 11). We
confirmed the increase in macrophages with topical vemurafenib
by IHC analysis (Supplementary Fig. 12). As expected, the
increase in macrophages was abolished with the co-administra-
tion of trametinib. To elaborate on the activated pathways asso-
ciated with the increased presence of wound-healing cell subsets
at this time point, we analysed for enriched gene ontology (GO)
biological processes on the genes up-expressed in the vemur-
afenib-treated wounds (Z2-fold increase) using ClueGo15. We
D14D6D2
Row Z-score
BR
AF
 s
ig
na
tu
re
W
ou
nd
 h
ea
lin
g 
sig
na
tu
re
VEM VEM CTRLCTRLCTRL VEM
–1 0 1
EGR1
TNFAIP3
LIF
LONRF3
GDF15
IER3
DUSP4
IER2
SLC43A3
SLC2A3
SPRY4
SSH1
SH2B3
BHLHE40
ST3GAL5
PMAIP1
MYC
ETV5
PFKFB4
DLX1
BMF
UCN2
LEF1
CCND1
LDLR
SERPINB8
DUSP6
SHISA2
TMEM87B
FAM84B
YPEL2
MAP2K3
JAG1
PLK3
E7
F10
CD36
PF4
WAS
SERPINE1
F2RL2
ADORA2A
ACVRL1
GNA12
GNAQ
PABPC4
RTN4RL2
TFP1
PROS1
TGFB2
PLAT
LMAN1
F2RL3
F13A1
ITGB3
GGCX
DCBLD2
GP1BA
ENTPD1
THBD
SPRR3
RTN4RL1
F5
EREG
MMRN1
GSVA
score
GSVA
score
0.251 0.400 –0.143 0.291
0.129 0.136 0.081 0.460 –0.294 –0.478
0.275 0.061 BRAF sig.
Wound
healing sig.
Figure 4 | Gene expression profiling of cutaneous wound healing in mice. Full-thickness skin resected around the areas of the initial wound was analysed
for gene expression profiling by RNASeq. Top, Expression, regulation and overall enrichment of BRAF signature genes as measurement of MAPK pathway
activity. Bottom, expression changes and enrichment of wound-healing signature genes (GO: 0042060). There is enrichment of the BRAF signature at day
2 and 6 in vemurafenib-treated wounds, with a significant increase of the wound-healing signature at day 6. Enrichment scores, GSVA (the scores are
normally distributed around 0 where negative values indicate relative de-enrichment of the signature and positive values indicate enrichment).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12348 ARTICLE
NATURE COMMUNICATIONS | 7:12348 | DOI: 10.1038/ncomms12348 | www.nature.com/naturecommunications 5
found clear enrichment of pathways involved in lymphocyte
activation, vascular development and response to wounding
(Fig. 5a). Integration of the enrichments of cell subset signatures,
gene and pathway upregulation showed enhanced recruitment of
wound-healing-specific cell subsets which results in stronger
activation of the inflammatory and angiogenic wound-healing
processes (Fig. 5b). To confirm these findings, the levels of COX-
2þ and IL-6þ cells were quantified by immunohistochemistry.
The wounds treated with vemurafenib had higher IL-6þ and
COX-2þ cells at the proliferation stage, on day 6
(Supplementary Fig. 13), which is consistent with our
integrated RNAseq data shown in Fig. 5b. As a further
verification of our RNAseq data, RT-PCR for Egr-1, TNFAIP3
and F7, for total skin wounds, was performed. These three genes
are upregulated in our gene signature (Fig. 5b) and our results on
the RT-PCR verified this increase in vemurafenib-treated wounds
by day 6 post treatment (Supplementary Fig. 14).
Enhanced angiogenesis with vemurafenib. To confirm the
beneficial effects of vemurafenib treatment on angiogenesis, we
quantified PECAM-1þ cells in the excisional and incisional
wound areas. In the excisional wound model there was a 74%
increase in the number of PECAM-1þ cells in vemurafenib-
treated wounds compared with the control wounds at day 6 post-
treatment (P¼ 0.006 by t-test n¼ 4; Fig. 6a). A 65% increase of
PECAM-1þ cells was observed in the incisional wound model in
wounds treated with vemurafenib (P¼ 0.02 by t-test), consistent
with the enrichment of endothelial cells observed in the RNASeq
data (Fig. 6b). This increase was reversed by the addition of
topical trametinib (0.2mg), with a 67% decrease in the number of
PECAM-1þ cells at day 6 (P¼ 0.01 by t-test; vemurafenib versus
vemurafenibþ trametinib). Trametinib alone completely depleted
PECAM-1þ cells (Fig. 6b).
Vemurafenib does not induce skin epidermal tumours. To
analyse the possibility of a cutaneous tumour-promoting activity
of topically applied vemurafenib, we used the well-established
two-stage skin carcinogenesis model16,17. Topical application of
DMBA or acetone was followed either with topical TPA as a
positive control for skin carcinogenesis or with topical
vemurafenib, twice a week for 15 weeks16. The only mice that
developed skin carcinogenesis were the group treated with DMBA
plus TPA (Fig. 7). No skin papillomas, keratoacanthomas or
squamous cell carcinomas occurred in mice treated with DMBA
plus vemurafenib at the concentrations that enhanced wound
healing (2mg) or higher (4mg). Therefore, topical vemurafenib
did not promote skin carcinogenesis even after mice were exposed
a
b
Figure 5 | Effect of vemurafenib on the biological pathways involved in wound healing. (a) Significantly activated biological process/pathways by day
6 of vemurafenib treatment based on the enriched gene ontology (GO) clusters visualized by ClueGO. (b) Integrated view highlighting specific
wound-healing cell subsets (red; with signature enrichments), their upregulated genes (yellow) and enriched wound-healing-related processes (blue) in the
transcriptome of mice wounds treated with vemurafenib by day 6. Gene node size represents induction at day 6, with the largest node representing a log2
(FC) of 4.54 and smallest node representing a log2 (FC) of 1.03.
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to an initiating carcinogen application that results in the presence
of epithelial cells bearing RAS mutations16,18.
Discussion
In the current work, we tested whether the skin hyperproliferative
side effects of BRAF inhibitors can be exploited to accelerate skin
wound healing by inducing paradoxical MAPK activation. These
findings show how the BRAF inhibitor vemurafenib enhances
proliferation and migration of keratinocytes in vitro and in two
in vivo mice models, when applied topically on the skin wounds
of mice.
Collectively, these studies demonstrate that the phenomenon
of paradoxical MAPK activation by BRAF inhibitors may be
exploited to enhance skin wound healing. Topical application of a
BRAF inhibitor resulted in the accelerated healing of skin wounds
by primarily acting on the proliferative stage of wound healing,
with improvement in multiple other events in wound healing
including inflammation and angiogenesis. These benefits were
offset by adding a MEK inhibitor that is known to inhibit
paradoxical MAPK activation18, while this topical therapy did not
result in tumour promotion. Therefore, topical BRAF Inhibitors
could be used to accelerate the healing of acute skin wounds, such
as abrasions and surgical incisions.
Methods
Data reporting. No statistical methods were used to predetermine sample size.
The experiments were not randomized. The investigators were not blinded to
allocation during experiments and outcome assessment.
Cell proliferation and migration assays. HEKa were purchased from Invitrogen
(Grand Island, NY; C-005-5C). HEKa cells (25,000 per well) were plated on 96-well
ImageLock cell migration plates (Essen Bioscience, Ann Arbor, MI, USA) and
incubated overnight. Then, the cell monolayer was scratched with a 96-pin
WoundMaker (Essen Bioscience), and the cells washed with PBS (phosphate-
buffered saline) before adding cell medium. Cells were maintained in culture with a
concentration of 1.5 mM of vemurafenib until complete scratch closure. Cell
migration was monitored by a microscope gantry inside a cell incubator, which was
connected to a networker external controller hard drive that gathered and
processed image data (Incucyte, Essen Bioscience, Ann Arbor, MI, USA). This
allows an automated and non-invasive method of monitoring live cells in culture.
HEKa and M249 cells were plated on OrisTM cell migration plates (Platypus
Technologies, Madison, WI, USA), treated with vehicle, vemurafenib (1.5 mM),
trametinib (1 mM), mitomycin C (10mgml 1), NSC 295642 (1mgml 1) or
combination, and loaded with CellTrackerTM Green CMFDA (5-chloromethyl-
fluorescein diacetate) probe (Life Technologies, Carlsbad, CA, USA). Mitomycin
C and NSC 295642 were purchase from Sigma-Aldrich, Sant Louis, MO, USA. Cell
migration was assessed using a BioSpot Series 5 UV analyzer (Cellular Technology
Limited, Cleveland, OH, USA).
Colony-forming assays. Twenty-four-well plates were covered with 300 ml of
serum-free RPMI 1640 (Fisher Scientific, Hampton, NH, USA) with 0.6% Noble
agar (BD Biosciences, San Jose, CA, USA), and incubated at 37 C overnight, until
solid. Three-hundred microlitres of a suspension of HEKa and M249 cells (15,000
cells per ml) in a 1:1 mixture of growth medium with a concentration of 1.5 mM of
vemurafenib and growth factor-reduced matrigel (BD Biosciences) were added to
each well. After 1 week, automated colony quantification was performed using a
BioSpot Series 5 UV analyzer.
Intracellular flow cytometry analysis. HEKa and M249 cells treated with a
concentration of 1.5 mM of vemurafenib or vehicle control were fixed with
formaldehyde to a final concentration of 1.6%, and permeabilized using methanol
(90%). Then, they were washed in staining buffer (sterile PBS, 0.5% BSA, 0.01%
sodium azide, NaN3), and stained with Alexa Flour 647 mouse anti-ERK1/2
(pT202/pY204) antibody and PE mouse anti-human Ki67 antibody (BD
Pharmingen, San Jose, CA, USA). After incubation, cells were washed again and
resuspended in 3ml of staining buffer. A total of 30,000 cellular events were
acquired for analysis. Data was analysed using FlowJo (Tree Star Inc., Ashland,
OR, USA). HEKa and M249 cells were routinely tested for mycoplasma and were
found to be negative.
Western blotting. M249 and HEKa cells were treated in duplicate with a
concentration of 1.5 mM of vemurafenib or vehicle control. Primary antibodies
included p-ERK Thr204/205 (1:1,000, #9101), ERK (1:1,000, #4094), Ki67 (1:1,000,
#9449) and beta-actin (1:3,500, #8457) (all from Cell Signalling Technology,
Danvers, MA, USA). Immuno-reactivity was revealed with an ECL-Plus kit,
using a Typhoon scanner (both from Amersham Biosciences Co, Piscataway, NJ,
USA)17. Uncropped scans of the most important immunoblots are shown in
Supplementary Fig. 15.
Incisional dorsal wound model. C3Hf/Kam (H2-k) female mice were used for
wound-healing studies at 8–10 weeks of age. They were bred at UCLA and used
under the Animal Research Council (ARC) protocol # 2013-066-01 ‘Wound-
Healing with BRAF inhibitors’. Full-thickness woundsB2.5 cm long were made in
the shaved dorsal skin of anaesthetized mice as described19, with ketamine/xylazine
as an anaesthetic. Clinical grade vemurafenib pills (Zelboraf, Genentech, South San
Francisco, CA, USA) were grinded and dissolved in dimethylsulfoxide (DMSO;
Fisher Scientific) and phosphate buffered saline (PBS; 1:4) to a concentration of
40 mgml 1 and 50 ml of the mixture (or DMSO in PBS as vehicle control) was
added topically. Wounds were closed with 3–4 clips, which were removed after
2 days. Vemurafenib suspension (2mg) or vehicle control was re-applied topically
to the wound site on days 2, 4, 6, 8, 10 and 12. Two weeks after wounding, a square
of skin containing the wound was removed from euthanized mice and cut into
seven 2-mm strips of 20mm in length with a multiblade device, so that each
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Figure 6 | Angiogenesis is increased in mice wounds treated with
vemurafenib. (a) Representative photomicrograph immunohistochemistry
images of PECAM-1þ cells in an excisional wound splinting model of mice
treated with vehicle or vemurafenib on day 6 post-treatment and bar graph,
on the right side, representing the quantification of PECAM-1þ cells on the
vehicle- and vemurafenib-treated wounds on day 6 (P¼0.006 by t-test;
n¼4). Wound area indicated with an arrow. (b) Representative
photomicrograph immunohistochemistry images of PECAM-1þ cells in an
incisional wound model of mice treated with vehicle, vemurafenib (VEM),
trametinib (TRAME) or the combination (VEMþTRAME); (P¼0.0002 by
one-way ANOVA). Trametinib alone completely depleted the number of
PECAM-1þ cells. Wound area between double head arrows. Error bars,
mean±s.d. Bar graphs represent one experiment with 4 replicates per
group.
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2-mm-wide strip contained a horizontal wound sample20. The strips were spread
on filter papers soaked in ice-cold PBS in covered Petri dishes until WTS
measurement, as previously described21 using an Instron tensiometer (Model 3342;
Instron, Norwood, MA, USA). The skin strips were stretched at a rate of
1 cmmin 1 to breaking point to obtain the peak WTS in gf per 2mm. The WTS of
unwounded skin from 12 weeks old mice is 250 gf (ref. 20).
Excisional skin wound splinting model. Seven- to nine-week old female Balb/c
mice were used for these studies under the ACR protocol #2010-011-13F. Mice
were anaesthetized with 2–3% isoflurane in an induction chamber and kept under
anaesthesia during the whole surgery. The back of the mice was shaved, washed
with betadine and 70% ethanol and a dose of buprenorphine (2.5mg kg 1) was
administered, subcutaneously, before the surgery. Two excisional wounds were
made in the skin aside the midline of the animal using a 6-mm biopsy punch.
Twenty microliter of vemurafenib (0.1mg ml 1) or DMSO was applied topically
on the wounds 1min before suturing of the splinting rings. The splinting rings
have an 8-mm transparent window, which was covered with Tegaderm to allow
visualization and measurement of the wound size. All animals were observed daily
for signs of inflammation and pain for the first 48 h post surgery. Vemurafenib or
DMSO was repeatedly applied on day 2 and 4. Wounds were photographed at day
0, day 2, day 6 and day 14, based on which the percentages of wound closure were
calculated.
Histological analyses. Dorsal skin wounds from CH3 mice treated with
vemurafenib suspension or DMSO in saline-control suspension were excised at day
2, 6 and 14. They were fixed in 10% neutral buffered formalin and embedded in
paraffin and stained with hematoxylin and eosin (H&E) using standard methods.
Balb/c mice were sacrificed at day 2, 6 and 14 with isoflurane overdose. Two 8-mm
round pieces of tissue were collected from each Balbc/c mouse containing the
whole-wound area and the surrounding tissue and skin, cut precisely in half at the
midline of the wound and fixed in 1% paraformaldehyde (PFA) for 16–18 h at 4 C,
dehydrated in 70% EtOH, and then paraffin embedded. Sections were cut at 4 mm,
deparaffinized with xylene and descendant ethanol and then incubated in 3% H2O2
for 10min. After a wash in distilled water, the slides were incubated for 25min in
citrate buffer pH6 (Invitrogen, Carlsbad, CA, USA) at 95 C using a vegetable
steamer. The slides were brought to room temperature, rinsed in PBST
(PBS-containing 0.05% Tween-20), and then incubated at room temperature with
1:100 Ki67 antibody (DAKO, Carpinteria, CA, USA), 1:1,000 PECAM-1 antibody
(Santa Cruz Biotechnology, Dallas, Texas) or 1:200 IL-6 antibody (Abcam,
Cambridge, MA, USA) for 1 h and 1:10 phospho-ERK Ab (Cell Signaling
Technology, Danvers, MA, USA), 1:1,500 CD68 antibody (Abcam, Cambridge,
MA, USA) or 1:25 COX-2 antibody (Cayman Chemical, Ann Arbor, MI) overnight
at 4 C. The stained slides were rinsed with PBST and incubated at room
temperature with 1:200 polyclonal Rabbit anti-rat immunoglobulin/Biotinylated
Ab (Dako, Carpinteria, CA #E0468) for 30min. All slides were rinsed with PBST,
and incubated with Dako EnVisionþ System –HRP Labelled Polymer Anti-Rabbit
(Dako, Carpinteria, CA, USA) at room temperature for 30min. After a rinse
with PBST, the slides were incubated with DAB (3,30-diaminobenzidine) for
visualization. Subsequently, the slides were washed in tap water, counterstained
with Harris’ Hematoxylin, dehydrated in ethanol, and mounted with media.
The imaging and quantification of our cell-based immunohistochemistry was
performed with the HALO Next Generation Imaging analysis software (Indica
Labs; Corrales, NM). HALO measures and reports individual cell data maintaining
an interactive link between cell metrics and cell imagery. The number of
pERKþ Ki67þ and PECAM-1þ cells was automatically counted with the HALO
software. Three 20 fields of view from each side of the wound were automatically
counted for pERK and Ki67 stains. PECAM-1þ and CD68þ cells were
automatically counted on each side of the wound edges where the granulation
tissue starts (1mm length each side) on the excisional wound-splinting model, and
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Figure 7 | Vemurafenib does not induce skin tumours when applied topically to mice. (a) Representative images of mice from each study group on week
15 of treatment. Topical application of 7,12-Dimethylbenz[a]anthracene (DMBA) to FvB/N mice followed by 12-O-tetradecanoylphorbol-13-acetate (TPA)
induced skin papillomas and squamous cell carcinomas by week 8 of treatment. In the control (DMBAþTPA) group all eight mice developed tumours.
In the groups with DMBA or acetone control, followed by topical application of vemurafenib (VEM, 2 or 4mg per mice) no skin tumours were induced.
(b) Graph representations of tumour count and percentage of tumour incidence per week. Error bars in b, mean±s.d.; n¼ 8.
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in the entire wound area on the incisional wound model. IL-6þ and COX-2þ
cells were automatically counted in the entire wound area on the incisional wound
model.
RNAseq analysis. RNA from mice skin samples in each treatment group were
extracted (RNeasy Mini Kit, Qiagen, Valencia, CA, USA) on days 2, 6 and 14
and sent for RNAseq analysis using 2 100 bp paired end Illumina HiSeq2000
(Illumina, San Diego, CA, USA) sequencing run. Raw sequences were mapped to
the mouse mm9 reference sequence by TOPHAT. The normalized gene expression
levels of each were expressed in FPKM values as generated by the programme
cuffquant and cuffnorm on TOPHAT’s BAM output19. We applied the options
‘--frag-bias-correct’, ‘--multi-read-correct’ and ‘--compatible-hits-norm’ on the
cuffquant run. The heatmap of the MAPK and wound-healing signatures was
generated based on the signature genes’ row-normalized FPKM levels by the R
package gplots. GSVA score was computed using normalized read counts as
described11. Normalized read counts (computed by Cuffnorm on the RNAseq
BAM files) of the mouse tissue with/without treatment of vemurafenib at day 2,
6 and 14 were supplied to the dermDB database13. Different immune cell-type gene
sets that we used were reported, previously22. Enrichment scores were computed as
the average difference of each gene in a gene set against its mean across all samples.
Row-normalized enrichment scores of the immune gene sets were visualized and
the P-values of the enrichment score differences were computed based on a null
distribution generated by permutation of the gene labels (n¼ 100,000). P-values
were adjusted using Benjamini–Hochberg method. Specific biological processes on
day 6 with vemurafenib treatment (with control day 6 as reference) were
nominated using GO enrichment analysis on the upregulated genes (minimum
2-fold upregulation) in the treated group. The enriched GO terms were computed
and visualized using ClueGO (ref. 15). The integrated panel highlighting relations
among enriched genes, gene processes and specific immune subsets was created
using the Gephi software23. The data was submitted to the GEO repository
(accession number GSE74558).
Quantitative PCR. q-PCR was performed using a one-step reverse transcription
kit developed specifically for SYBR Green-based real-time PCR (Power SYBR
Green RNA-to-CT 1-Step Kit, Thermo Fisher Scientific, Carlsbad, CA, USA), with
a standard quantitation-comparative Ct procedure as set by the manufacturer.
Triplicate reactions (25 ml) of each experimental sample were prepared with the
following primers: TNFAIP3 (Fwd: 50- CTGACCTGGTCCTGAGGAAG -30 ; Rev:
50- GCAAAGTCCTGTTTCCA-30), F7 (Fwd: 50 GACTTTGACGGTCGGAACT
GTG 30 ; Rev: 50 GCGGCTGCTGGAGTTTCTTT 30) and Egr-1 (Fwd: 50-GACGA
GTTATCCCAGCCAAA-30 ; Rev: 50-GGCAGAGGAAGACGATGAAG-30). Data
were normalized to Bactin levels.
Carcinogenesis studies. Female FVB/N mice were purchased from Charles River
Laboratory (Wilmington, MA, USA). Tumour induction procedures were carried
out in accordance with ARC protocol #2013-066. The two-stage carcinogenesis
procedures were performed as described previously24,25 with 8 mice per group.
DMBA and TPA were purchased from Sigma. Clinical grade vemurafenib pills
were grinded and dissolved in DMSO; to a concentration of 0.02 and 0.04mg ml 1
and 100 ml of the mixtures (or DMSO as vehicle control) was added topically on the
back of the mice. Vemurafenib suspension (2 or 4mg) or vehicle control was
re-applied topically to the back of the mice twice a week for 15 weeks.
Statistical analysis. Data were analysed with GraphPad Prism (version 5)
software (GraphPad Software, La Jolla, CA, USA). Significance was determined
by unpaired two-tailed Student’s t-test or one-way analysis of variance (ANOVA).
Variance was similar between the groups that were statistically compared.
Data availability. All relevant data are included with the manuscript as figure
source data or Supplementary Information Files. The RNAseq data can be accessed
at the GEO repository (accession number GSE74558).
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